Global Alopecia Areata Market – Industry Trends and Forecast to 2030

Global Alopecia Areata Market, By Type (Patchy Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Diffuse Alopecia Areata, Ophiasis Alopecia, Others), Diagnosis (Trichoscopy, Skin Biopsy, Others), Treatment (Medical Treatments, Natural Treatment, Others), Route of Administration (Oral, Topical, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.

Alopecia Areata Market Analysis and Size

An autoimmune disorder known as alopecia areata causes sporadic hair loss. The National Institute for Health and Care Excellence (NICE) predicted that in 2020, there would be 15 cases of alopecia per 10,000 people in the U.K. Although it can afflict anyone at any age, it is most common in childhood and adolescents. The incidence peaked between the ages of 15 and 29. Before age 21, 50–60% of boys have their first bald spot.

Data Bridge Market Research analyzes that the global alopecia areata market which was USD 3.01 billion in 2022, is likely to reach USD 5.00 billion by 2030, and is expected to undergo a CAGR of 6.3% during the forecast period. “Patchy alopecia areata” dominates the type segment of the myositis treatment market due to the increasing prevalence of hair loss among the population. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Alopecia areata (AA) is an autoimmune disease that causes hair to fall out in small, unnoticed patches that eventually become apparent when the hair grows back. When the autoimmune system attaches to the hair follicles, hair loss occurs. Alopecia universalis is a condition that causes total hair loss and prevents hairs from returning. However, the severity of the condition varies from person to person. Hair loss can affect other parts of the body and the face, such as the eyebrows, eyelashes, and beard. When it comes to hair loss, men are more likely than women to have a family history of it.

Global Alopecia Areata Market Dynamics

Drivers

• Increasing prevalence of hair loss

The rising prevalence of hair loss is estimated to enhance the alopecia areata market's growth. In 2018, the American Academy of Dermatology Association (AAD) projected that about 50 million men and 30 million women in the United States were plagued with alopecia. According to the Journal of Clinical and Diagnostic Research (JCDR), around 60% of the population suffers from hair thinning, with pattern hair loss being the most common in both men and women. Furthermore, roughly 2% of the entire population, regardless of gender, is at risk of acquiring alopecia areata in their lifetime.

• Increasing investment in healthcare infrastructure

Another significant factor influencing the growth rate of the alopecia areata market is the rising healthcare expenditure which helps improve its infrastructure. An increase in healthcare expenditure is being driven by an increase in the number of activities conducted by organizations such as the National Alopecia Areata Foundation and the American Hair Loss Association to raise awareness about hair regrowth and treatment alternatives.

  Opportunities

• Increasing therapeutic developments

Finding novel and better therapies for alopecia areata is the subject of continuous research and development in the field. Pharmaceutical and biotech businesses have an opportunity to create novel treatments that can target the underlying causes of alopecia areata and encourage hair regeneration.

• Growing demand for hair transplantation

Alopecia areata patients with extensive or permanent hair loss frequently choose surgical hair transplantation. The availability of more hair transplantation treatments and the development of better techniques may open up new business options for hair restoration clinics.

• Increasing awareness regarding the disease

In recent years, there has been a substantial rise in public awareness of alopecia areata. Patients are learning more about the illness, its signs and symptoms, and the various therapies. Because of the higher diagnosis rates and greater demand for treatments as a result of this improved knowledge, there is potential for market expansion.

Restraints/Challenges

• Strict regulatory framework

Regulatory procedures and standards are involved in the creation and approval of new alopecia areata remedies. Clinical studies, regulatory compliance, and approval processes can be time- and money-consuming. These regulatory difficulties may prevent the commercialization of innovative treatments, thus reducing patient treatment alternatives.

• High cost of treatment

Some alopecia areata treatment options, like immunotherapy or hair transplantation, might be pricey. The high price of these medicines may make them inaccessible to some patient populations, hence restricting the market's potential for expansion. Patients seeking thorough and successful therapy may encounter substantial obstacles related to cost and insurance coverage.

• Limited treatment options

There are currently few treatments available for alopecia areata despite continued research and advances. Since the condition's precise aetiology is still not fully known, it is difficult to create specialized and efficient treatments. This restriction makes it more difficult to expand the market and give patients satisfying options.

• Adverse effects of treatment

Corticosteroids and immunosuppressants are two treatments for alopecia areata that may have unfavorable side effects. The long-term use of such treatments is constrained by these adverse effects, which might range from local skin reactions to systemic impacts. The possibility of negative effects makes it difficult for patients and healthcare professionals to accept and use available treatment choices.

This alopecia areata market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the alopecia areata market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In March 2023, Sun Pharmaceuticals Industries Ltd., a global pharmaceutical company, declared a phase 3 clinical trial data presentation for analyzing deuruxolitinib, an oral medicine to help in improving the scalp hair regrowth in patients with alopecia areata
• In June 2023, Pfizer Inc., a multinational biotechnology and pharmaceutical company, notified that the US Food and Administration (FDA) approved LITFULOTM (ritlecitinib), an oral treatment for 12 years and above individuals with severe alopecia areata. This approval resulted in making LITFULOTM an advanced treatment for people with alopecia areata

Global Alopecia Areata Market Scope

The alopecia areata market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Patchy Alopecia Areata
• Alopecia Totalis
• Alopecia Universalis
• Diffuse Alopecia Areata
• Ophiasis Alopecia
• Others

Treatment

• Medical Treatments
• Topical agents
• Steroid injections
• Oral immunosuppressants
• Light therapy
• Others
• Natural Treatment
• Herbal supplements
• Aromatherapy
• Micro-needling
• Acupuncture
• Probiotics
• Others

Diagnosis

• Trichoscopy
• Skin Biopsy
• Others

Route of Administration

• Oral
• Topical
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Alopecia Areata Market Regional Analysis/Insights

The alopecia areata market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, rest of Middle East & Africa.

North America is expected to dominate the market due to the growing prevalence of autoimmune diseases in this region. In addition, rising healthcare expenditure will further propel the market’s growth rate in this region.

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to easily availability of over-the-counter (OTC) drugs and surging hair loss treatment by herbal and synthetic medicines in this region. Also, the development of healthcare infrastructure will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The alopecia areata market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the alopecia areata market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the alopecia areata market.

Competitive Landscape and Alopecia Areata Market Share Analysis

The alopecia areata market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the alopecia areata market.

Some of the major players operating in the alopecia areata market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Eli Lilly and Company (U.S.)
• Merck & Co., Inc. (U.S.)
• Allergan (Ireland)
• AstraZeneca (U.K.)
• AbbVie Inc. (U.S.)
• Johnson & Johnson Services Inc. (U.S.)
• Cipla Inc. (India)  
• Abbott (U.S.)
• Merck KGaA (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin Ltd (India)
• Hikma Pharmaceuticals PLC (U.K.)
• LEO Pharma A/S (Denmark)
• Bausch Health Companies Inc. (Canada)
• Baxter (U.S.)
• Perrigo Company plc (Ireland)